PMID- 26756887
OWN - NLM
STAT- MEDLINE
DCOM- 20160803
LR  - 20210103
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 138
IP  - 11
DP  - 2016 Jun 1
TI  - The influence of myeloid-derived suppressor cells on angiogenesis and tumor 
      growth after cancer surgery.
PG  - 2688-99
LID - 10.1002/ijc.29998 [doi]
AB  - While myeloid-derived suppressor cells (MDSCs) have been reported to participate 
      in the promotion of angiogenesis and tumor growth, little is known about their 
      presence and function during perioperative period. Here, we demonstrated that 
      human MDSCs expressing CD11b(+), CD33(+) and HLA-DR(-) significantly increased in 
      lung cancer patients after thoracotomy. CD11b(+) CD33(+) HLA-DR(-) MDSCs isolated 
      24 hr after surgery from lung cancer patients were more efficient in promoting 
      angiogenesis and tumor growth than MDSCs isolated before surgical operation in 
      allograft tumor model. In addition, CD11b(+) CD33(+) HLA-DR(-) MDSCs produced 
      high levels of MMP-9. Using an experimental lung metastasis mouse model, we 
      demonstrated that the numbers of metastases on lung surface and Gr-1(+) CD11b(+) 
      MDSCs at postoperative period were enhanced in proportion to the degree of 
      surgical manipulation. We also examined that syngeneic bone marrow mesenchymal 
      stem cells (BMSCs) significantly inhibited the induction and proliferation of 
      Gr-1(+) CD11b(+) MDSCs and further prevented lung metastasis formation in the 
      mice undergoing laparotomy. Taken together, our results suggest that 
      postoperatively induced MDSCs were qualified with potent proangiogenic and 
      tumor-promotive ability and this cell population should be considered as a target 
      for preventing postoperative tumor metastasis.
CI  - (c) 2016 UICC.
FAU - Wang, Jun
AU  - Wang J
AD  - Department of Anesthesiology, The First Affiliated Hospital of Kunming Medical 
      University, Kunming, China.
FAU - Su, Xiaosan
AU  - Su X
AD  - Biomedical Research Center, The First Hospital of Kunming (the Affiliated 
      Calmette Hospital of Kunming Medical University), Kunming, China.
FAU - Yang, Liu
AU  - Yang L
AD  - Biomedical Research Center, The First Hospital of Kunming (the Affiliated 
      Calmette Hospital of Kunming Medical University), Kunming, China.
FAU - Qiao, Fei
AU  - Qiao F
AD  - Department of Anesthesiology, The First Affiliated Hospital of Kunming Medical 
      University, Kunming, China.
FAU - Fang, Yu
AU  - Fang Y
AD  - Department of Anesthesiology, The First Affiliated Hospital of Kunming Medical 
      University, Kunming, China.
FAU - Yu, Lu
AU  - Yu L
AD  - Department of Pathology, The First Hospital of Kunming (the Affiliated Calmette 
      Hospital of Kunming Medical University), Kunming, China.
FAU - Yang, Qian
AU  - Yang Q
AD  - Biomedical Research Center, The First Hospital of Kunming (the Affiliated 
      Calmette Hospital of Kunming Medical University), Kunming, China.
FAU - Wang, Yiyin
AU  - Wang Y
AD  - Biomedical Research Center, The First Hospital of Kunming (the Affiliated 
      Calmette Hospital of Kunming Medical University), Kunming, China.
FAU - Yin, Yanfeng
AU  - Yin Y
AD  - Biomedical Research Center, The First Hospital of Kunming (the Affiliated 
      Calmette Hospital of Kunming Medical University), Kunming, China.
FAU - Chen, Rui
AU  - Chen R
AD  - Biomedical Research Center, The First Hospital of Kunming (the Affiliated 
      Calmette Hospital of Kunming Medical University), Kunming, China.
FAU - Hong, Zhipeng
AU  - Hong Z
AD  - Department of Thoracic Surgery, The First Affiliated Hospital of Kunming Medical 
      University, Kunming, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160125
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (CD11b Antigen)
RN  - 0 (CD33 protein, human)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (ITGAM protein, human)
RN  - 0 (Sialic Acid Binding Ig-like Lectin 3)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
SB  - IM
MH  - Animals
MH  - CD11b Antigen/genetics
MH  - Cell Proliferation/*genetics
MH  - Flow Cytometry
MH  - HLA-DR Antigens/genetics
MH  - Humans
MH  - Lung Neoplasms/pathology/surgery/*therapy
MH  - Matrix Metalloproteinase 9/biosynthesis
MH  - Mice
MH  - Myeloid Cells/*transplantation
MH  - Neoplasm Metastasis
MH  - Neovascularization, Pathologic/pathology/*therapy
MH  - Sialic Acid Binding Ig-like Lectin 3/genetics
MH  - Xenograft Model Antitumor Assays
OTO - NOTNLM
OT  - bone marrow mesenchymal stem cells
OT  - lung cancer
OT  - metastasis
OT  - myeloid-derived suppressor cells
OT  - perioperative period
EDAT- 2016/01/13 06:00
MHDA- 2016/08/04 06:00
CRDT- 2016/01/13 06:00
PHST- 2015/06/04 00:00 [received]
PHST- 2015/12/15 00:00 [revised]
PHST- 2015/12/17 00:00 [accepted]
PHST- 2016/01/13 06:00 [entrez]
PHST- 2016/01/13 06:00 [pubmed]
PHST- 2016/08/04 06:00 [medline]
AID - 10.1002/ijc.29998 [doi]
PST - ppublish
SO  - Int J Cancer. 2016 Jun 1;138(11):2688-99. doi: 10.1002/ijc.29998. Epub 2016 Jan 
      25.